17 completed, 3 withdrawn, 2 terminated. 14 Phase 2, 8 Phase 1, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 10, Withdrawn 3, Terminated 1 |
| Phase 1 | 8 | Completed 7, Terminated 1 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Peregrine Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma Temozolomide, Bavituximab, Radiation - Glioblastoma | Phase 2 | Completed | Massachusetts General Hospital | 36 | 2017-09-13 | 2024-05-16 |
| A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer Bavituximab, Taxane - Breast Cancer, Triple Negative Breast Neoplasms | Phase 2 | Withdrawn | Peregrine Pharmaceuticals | 2016-03-01 | 2017-03-09 | |
| Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer durvalumab, bavituximab - Non-Small Cell Lung Cancer | Phase 2 | Withdrawn | Peregrine Pharmaceuticals | 2016-02-01 | 2016-08-01 | |
| Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer Bavituximab, Taxane - Metastatic Breast Cancer | Phase 2 / Phase 3 | Withdrawn | Peregrine Pharmaceuticals | 2015-12-01 | 2017-07-11 | |
| Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer bavituximab, Docetaxel, Placebo (for bavituximab) - Non-Small-Cell Lung Cancer Stage IIIB, Non-Small-Cell Lung Cancer Stage IV | Phase 3 | Completed | Peregrine Pharmaceuticals | 582 | 2013-12-01 | 2017-04-21 |
| Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors I-124 PGN650 for PET/CT - Malignant Solid Tumor | Early Phase 1 | Terminated | Peregrine Pharmaceuticals | 11 | 2012-06-01 | 2017-07-11 |
| Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer Cabazitaxel plus bavituximab - Prostate Cancer, Prostatic Neoplasms | Phase 1 / Phase 2 | Terminated | Medical University of South Carolina | 4 | 2011-06-01 | 2018-07-13 |
| Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects Bavituximab - Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | UNC Lineberger Comprehensive Cancer Center | 26 | 2011-05-01 | 2018-12-04 |
| Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection Bavituximab, Pegylated interferon (PEG-IFN) - Hepatitis C | Phase 1 / Phase 2 | Completed | Peregrine Pharmaceuticals | 66 | 2011-01-01 | 2012-02-06 |
| Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer bavituximab, Gemcitabine - Metastatic Pancreatic Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 70 | 2011-01-01 | 2017-04-19 |
| Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer Docetaxel plus bavituximab or placebo - Non-small-cell Lung Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 121 | 2010-06-01 | 2017-04-19 |
| Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer Paclitaxel / Carboplatin, bavituximab - Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 86 | 2010-06-01 | 2017-04-19 |
| Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer Bavituximab - Carcinoma Breast Stage IV | Phase 2 | Completed | Peregrine Pharmaceuticals | 46 | 2008-07-01 | 2011-03-24 |
| Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer bavituximab plus paclitaxel and carboplatin - Non-small Cell Lung Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 49 | 2008-06-01 | 2011-03-24 |
| A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer Bavituximab - Breast Cancer | Phase 2 | Completed | Peregrine Pharmaceuticals | 46 | 2008-01-01 | 2017-04-21 |
| Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse 131I-chTNT-1/B MAb (Cotara) - Glioblastoma Multiforme | Phase 2 | Completed | Peregrine Pharmaceuticals | 41 | 2007-07-01 | 2014-04-24 |
| Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus bavituximab - Hepatitis C Virus, Hiv Infections | Phase 1 | Completed | Peregrine Pharmaceuticals | 24 | 2007-07-01 | 2011-06-09 |
| Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme 131-I-chTNT-1/B MAB - Recurrent Glioblastoma Multiforme | Phase 1 | Completed | Peregrine Pharmaceuticals | 12 | 2006-11-01 | 2011-08-05 |
| Repeat-Dose Study of Bavituximab in Patients With Chronic Hepatitis C bavituximab - Hepatitis C | Phase 1 | Completed | Peregrine Pharmaceuticals | 24 | 2006-05-01 | 2008-05-07 |
| Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection Bavituximab - Hepatitis C | Phase 1 | Completed | Peregrine Pharmaceuticals | 32 | 2005-08-01 | 2008-05-07 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (6) · Breast Neoplasms (4) · Glioblastoma (4) · Hepatitis C (4) · Brain Neoplasms (3) · Lung Neoplasms (2) · Astrocytoma (1) · Central Nervous System Neoplasms (1) · Gliosarcoma (1) · HIV Infections (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
bavituximab (18) · 131I-chimeric TNT-1-B monoclonal antibody (3) · Docetaxel (3) · Paclitaxel (3) · taxane (2) · CP protocol (1) · Carboplatin (1) · Gemcitabine (1) · Radiation (1) · Temozolomide (1) · cabazitaxel (1) · durvalumab (1) · peginterferon alfa-2a (1)
United States (16) · India (5) · Georgia (4) · Ukraine (4) · Russia (3) · Australia (1) · Belgium (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Romania (1) · South Korea (1) · Spain (1)
Andrew E Sloan, MD, FACS (1) · David E Gerber, MD (1) · David Page, MD (1) · Deepak K Gupta, MBBS,MS,MCh (1) · Eliot W Godofsky, MD (1) · Eliot W Godofsky, MD, FACP (1) · Elizabeth R Gerstner, MD (1) · Eric Lawitz, MD (1) · Farrokh Dehsashti, M.D. (1) · Janet Nuttall, MPH (1) · Jihad Slim, MD (1) · Jorge Rodriguez, MD (1) · Juneko Grilley Olson, MD (1) · Kathy Miller, MD (1) · Kenneth M Spicer, MD PhD (1)
PMID 25236982, PMID 29767677, PMID 37327319
2015 (1)